Life Science
With the presence of over 1000 biotech and life science companies, the Baltic Sea Region (BSR) is making its presence felt in the life science and pharmaceutical sector. While the strong human- capital base in the region provides for an easy outlet for the products to be developed and tested, R&D, which forms the backbone for any biotech industry, finds strong support with over 60 universities working on it. This has proved to be a boon to the pharmaceutical companies wanting to invest in the region.
Comparitive advantages in the Region:
The Baltic Sea Region enjoys the twin advantage of highly developed research and development tradition with that of human capital. The scientific communities, known for their strong tradition of international academic cooperation, work in close tandem with businesses and government. Listed below are the advantages enjoyed by the industry:
- Strong, competitive brands (AstraZeneca, LEO Pharma, Lundbeck, Novo Nordisk, Fermentas, Asla Biotech)
- Strong biotech competences united into a super-cluster through the ScanBalt BioRegion initiative
- Opportunities in clinical trials and medical technology
- Coordination, cooperation and communication services to maximize knowledge flows;
- Wide experience of work with funding bodies (EU, Nordic Innovation Centre and others);
- Commitment to multinational cooperation;
- Specializations in stem-cell research, marine biotechnology and agro-biotech, etc. among many others
Presence of brands in the Baltic Sea Region:
With a strong background for R&D along with the advantages of product promotion, Baltic Sea Region has seen a number of investments from different companies in its region, some of which includes:
- Sweden: Astra Zeneca, Pfizer, Biovitrum, Electa
- Denmark: Novo Nordisk, Nycomed
- Finland: Raisio
- Lithuania: Fermentas, Sicor Biotech
- Latvia: Asla Biotech, Biosan, Grindex
- Estonia: Celecure
Biotechnology is also an important sector for investment from different parts of the world. Seeing the immense potential for this sector, many European and Asian countries have tied up with the biotech companies from the Baltic Sea Region, some of which are given below:
- Australia: Biocel, Griffith University
- Canada: PerkinElmer BioSignal Inc.
- China: Interpharma Asia Pacific, Shanghai Jiaotong University
- Germany: Conaris Research Institute, Schering, Schwartz Pharma, Qiagen
- India: Biocon, Kemwell
- Japan: Dainippon Sumitomo Pharmaceuticals Co. Ltd., Astellas Pharmaceutical Ltd, Eisai
- UK: Astex Ltd., Cambridge Antibody Technology, Procardis, Prostrakan
- USA: MediQuest Therapeutics, Davos Chemical CA, Inc., Egeen, Quintiles, Abgenix Inc., Array Biopharma Inc., Beyond Genomics Inc., NeoGenesis Pharmaceuticals Inc., GE Health Care, Pfizer
Table1:
|
|||||||||||||||||||||||||||||||||||||
Table2:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
768Kb